Genfit S.A. Total Assets
Genfit S.A. total assets. Based on the latest financial reports, Genfit S.A. (GNFT) holds total assets worth €157.93 Million EUR (≈ $184.64 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see GNFT company net worth for the company's overall valuation and market capitalisation.
Total Assets of Genfit S.A. (2003–2025)
Total assets of Genfit S.A. from 2003 to 2025. This chart illustrates how Genfit S.A.'s total assets have evolved over time, based on quarterly financial data. See current stock price of Genfit S.A. for real-time trading data and today's change.
Genfit S.A. - Asset Composition Analysis
Genfit S.A. Total Assets Breakdown (December 2025)
Genfit S.A. total assets breakdown as of December 2025. Genfit S.A.'s total assets of €157.93 Million consist of 91.4% current assets and 8.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 64.0% |
| Accounts Receivable | €40.33 Million | 25.5% |
| Inventory | €4.00K | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €4.16 Million | 2.6% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2003–2025)
This chart illustrates how Genfit S.A.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Genfit S.A. (GNFT) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Genfit S.A.'s current assets represent 91.4% of total assets in 2025, an increase from 0.0% in 2003.
- Cash Position: Cash and equivalents constituted 64.0% of total assets in 2025, up from 0.0% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 1.0% in 2003.
- Asset Diversification: The largest asset category is accounts receivable at 25.5% of total assets.
Genfit S.A. Competitors by Total Assets
Key competitors of Genfit S.A. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Genfit S.A. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.00 | 1.23 | 5.95 |
| Quick Ratio | 2.00 | 1.23 | 5.95 |
| Cash Ratio | 1.40 | 1.09 | 0.00 |
| Working Capital | €71.97 Million | €17.60 Million | €153.65 Million |
Genfit S.A. - Advanced Valuation Insights
This section examines the relationship between Genfit S.A.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.60 |
| Latest Market Cap to Assets Ratio | 4.03 |
| Asset Growth Rate (YoY) | 4.3% |
| Total Assets | €157.93 Million |
| Market Capitalization | $636.05 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Genfit S.A.'s assets at a significant premium (4.03x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Genfit S.A.'s assets grew by 4.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Genfit S.A. (2003–2025)
The table below shows the annual total assets of Genfit S.A. from 2003 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €157.93 Million ≈ $184.64 Million |
+4.30% |
| 2024-12-31 | €151.42 Million ≈ $177.03 Million |
-12.91% |
| 2023-12-31 | €173.87 Million ≈ $203.27 Million |
-19.33% |
| 2022-12-31 | €215.54 Million ≈ $251.99 Million |
-23.49% |
| 2021-12-31 | €281.72 Million ≈ $329.36 Million |
+41.84% |
| 2020-12-31 | €198.61 Million ≈ $232.20 Million |
-35.90% |
| 2019-12-31 | €309.85 Million ≈ $362.25 Million |
+35.03% |
| 2018-12-31 | €229.48 Million ≈ $268.28 Million |
-21.73% |
| 2017-12-31 | €293.18 Million ≈ $342.76 Million |
+76.39% |
| 2016-12-31 | €166.21 Million ≈ $194.32 Million |
+139.99% |
| 2015-12-31 | €69.26 Million ≈ $80.97 Million |
-19.81% |
| 2014-12-31 | €86.37 Million ≈ $100.97 Million |
+196.27% |
| 2013-12-31 | €29.15 Million ≈ $34.08 Million |
+23.62% |
| 2012-12-31 | €23.58 Million ≈ $27.57 Million |
-18.90% |
| 2011-12-31 | €29.08 Million ≈ $33.99 Million |
-7.36% |
| 2010-12-31 | €31.39 Million ≈ $36.69 Million |
-18.32% |
| 2009-12-31 | €38.43 Million ≈ $44.93 Million |
-16.45% |
| 2008-12-31 | €45.99 Million ≈ $53.77 Million |
+14.37% |
| 2007-12-31 | €40.21 Million ≈ $47.01 Million |
-13.04% |
| 2006-12-31 | €46.24 Million ≈ $54.06 Million |
+49.98% |
| 2005-12-31 | €30.83 Million ≈ $36.05 Million |
+0.75% |
| 2004-12-31 | €30.61 Million ≈ $35.78 Million |
+17.10% |
| 2003-12-31 | €26.14 Million ≈ $30.56 Million |
-- |
About Genfit S.A.
Genfit S.A., together with its subsidiaries, engages in the research and development of medicines and diagnostic solutions in France and internationally. The company offers elafibranor for the treatment of primary biliary cholangitis; and NIS, a non-invasive diagnostic technology for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops elafibranor, which is in Phase… Read more